RxDoctor Payments Data

Joseph Tynes, MD

Internal Medicine · Shreveport, LANPI 1306880778

Payments from drug & device makers

$369in general payments, 2019–2025

Across 22 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$78
  • Lilly USA, LLC$48
  • Amgen$45
  • Pfizer$32
  • Abiomed$25
  • Dexcom, Inc.$25
  • plus $117 from 7 others

What the payments were for

  • Food & beverage$369100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$369 in reported general payments places this provider in the 45th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$201,199
Medicare patients
2,012
Services billed
3,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide137$159,036
OzempicSemaglutide71$82,144
JardianceEmpagliflozin48$58,718
JanuviaSitagliptin Phosphate35$57,147
EliquisApixaban30$44,951
LinzessLinaclotide17$21,216
JanumetSitagliptin Phos/Metformin Hcl13$15,832
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,512
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med47$3,301
Albuterol Sulfate HfaAlbuterol Sulfate76$2,956
Olmesartan Medoxomil164$2,692
Atorvastatin Calcium292$2,467
Rosuvastatin Calcium211$2,423
Pantoprazole Sodium171$2,230
Levothyroxine Sodium235$2,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$48$159,036137 claims
Novo NordiskOzempic$14$82,14471 claims
MerckJanuvia, Janumet$15$72,97948 claims
Boehringer IngelheimJardiance$78$58,71848 claims
PfizerEliquis$32$44,95130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →